179 related articles for article (PubMed ID: 32636928)
1. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials.
Wang D; Yang X; Lin J; Bai Y; Long J; Yang X; Seery S; Zhao H
Therap Adv Gastroenterol; 2020; 13():1756284820932483. PubMed ID: 32636928
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Chen J; Wang J; Xie F
Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis.
Solimando AG; Susca N; Argentiero A; Brunetti O; Leone P; De Re V; Fasano R; Krebs M; Petracci E; Azzali I; Nanni O; Silvestris N; Vacca A; Racanelli V
Clin Exp Med; 2022 Feb; 22(1):65-74. PubMed ID: 34146196
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety.
Merle P; Kudo M; Krotneva S; Ozgurdal K; Su Y; Proskorovsky I
Liver Cancer; 2023 Jun; 12(2):145-155. PubMed ID: 37325487
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma.
Delos Santos S; Udayakumar S; Nguyen A; Ko YJ; Berry S; Doherty M; Chan KKW
Curr Oncol; 2020 Dec; 27(6):300-306. PubMed ID: 33380861
[TBL] [Abstract][Full Text] [Related]
7. Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bakouny Z; Assi T; El Rassy E; Nasr F
J Clin Gastroenterol; 2019 Apr; 53(4):251-261. PubMed ID: 30575632
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
[TBL] [Abstract][Full Text] [Related]
9. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review.
Wu Y; Fan Y; Dong D; Dong X; Hu Y; Shi Y; Jing J; Li E
Ther Adv Med Oncol; 2020; 12():1758835920940932. PubMed ID: 32728393
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
[TBL] [Abstract][Full Text] [Related]
13. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
Llovet JM; Montal R; Villanueva A
J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy and Safety of Different Regimens of Advanced Gastrointestinal Stromal Tumors After Failure Prior Tyrosine Kinase Inhibitors: A Network Meta-Analysis.
Zhang X; Liang Y; Li Y; Yin J
Adv Ther; 2021 Jan; 38(1):399-412. PubMed ID: 33131035
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials.
Park R; Lopes da Silva L; Nissaisorakarn V; Riano I; Williamson S; Sun W; Saeed A
J Hepatocell Carcinoma; 2021; 8():145-154. PubMed ID: 33791250
[TBL] [Abstract][Full Text] [Related]
17. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of systemic therapy for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
Wu D; Jia B; Jia M; Zhao H; Zhao H; Zhou J
Front Oncol; 2023; 13():1274754. PubMed ID: 38125936
[TBL] [Abstract][Full Text] [Related]
19. Impact of post-progression survival in second-line treatment with molecular target agents for unresectable hepatocellular carcinoma.
Tajiri K; Muraishi N; Murayama A; Hayashi Y; Yasuda I
Hepatol Res; 2024 Apr; 54(4):403-408. PubMed ID: 37924508
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies.
Yen CJ; Kudo M; Lim HY; Hsu CH; Vogel A; Brandi G; Cheng R; Nitu IS; Abada P; Hsu Y; Zhu AX; Kang YK
Liver Cancer; 2020 Aug; 9(4):440-454. PubMed ID: 32999870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
